TY - JOUR A2 - Abdulhay, Enas AU - Deng, yanglin AU - Chen, Su AU - Wang, Hong-tu AU - Wang, Bo AU - Xiao, Kai PY - 2021 DA - 2021/09/29 TI -处方Sageretia hamosa Brongn通过miR-511-3p和PTEN/PI3K/Akt通路促进甲状腺细胞凋亡，缓解甲状腺肿 Sageretia hamosa Brongn(SHB)可用于治疗甲状腺肿，但未见报道。因此，本研究对SHB治疗甲状腺的处方进行数据分析，为SHB治疗甲状腺肿提供理论支持。采用丙基硫氧嘧啶(PTU)建立甲状腺肿大鼠模型，用SHB治疗。采用ELISA法测定三碘甲状腺原氨酸(T3)、游离甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)和促甲状腺激素(TSH)的甲状腺功能;甲状腺称重后计算甲状腺系数;HE染色评价甲状腺组织形态。miRNA微阵列检测大鼠甲状腺组织中miRNA的表达。RT-qPCR检测miR-511-3p的表达;western blotting检测PTEN和凋亡相关蛋白的表达;采用双荧光素酶报告基因检测miR-511-3p与PTEN的关系; cell viability rate was determined by CCK-8; and cell cycle distribution and apoptosis rate were detected by flow cytometry. The results showed that SHB prescription ameliorated goiter and downregulated miR-511-3p. miR-511-3p targeted PTEN in thyroid cells and PTEN negatively regulated the activation of PI3K/Akt pathway. Furthermore, the inhibition of apoptosis in thyroid cells caused by the overexpression of miR-511-3p or the activation of PI3K/Akt pathway was reversed by treatment of SHB prescription, inhibition of miR-511-3p, or overexpression of PTEN. In conclusion, SHB prescription promoted apoptosis of thyroid through decreased miR-511-3p and regulated PTEN/PI3K/Akt pathway, it might suggest possible medical applications. SN - 2040-2295 UR - https://doi.org/10.1155/2021/3506559 DO - 10.1155/2021/3506559 JF - Journal of Healthcare Engineering PB - Hindawi KW - ER -